Abbott Laboratories (NYSE:ABT) updated its first quarter 2020
Pre-Market earnings guidance on Wednesday. The company provided earnings per share guidance of 0.69-0.71 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.72. Abbott Laboratories also updated its FY 2020
Pre-Market guidance to 3.55-3.65 EPS.
Several equities analysts have recently commented on the company. ValuEngine lowered Abbott Laboratories from a buy rating to a hold rating in a report on Wednesday, October 2nd. Guggenheim lowered Abbott Laboratories from a buy rating to a neutral rating in a report on Thursday, January 2nd. Morgan Stanley upped their target price on Abbott Laboratories from $93.00 to $101.00 and gave the company an overweight rating in a report on Tuesday, December 17th. William Blair reaffirmed an underperform rating on shares of Abbott Laboratories in a report on Thursday, October 17th. Finally, Credit Suisse Group upped their target price on Abbott Laboratories from $95.00 to $98.00 and gave the company an outperform rating in a report on Thursday, October 17th. Two analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company’s stock. Abbott Laboratories has a consensus rating of Hold and an average price target of $94.00.
Shares of NYSE ABT opened at $91.86 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.12 and a debt-to-equity ratio of 0.55. The stock has a 50 day simple moving average of $86.69 and a 200-day simple moving average of $84.74. The company has a market cap of $158.68 billion, a PE ratio of 49.92, a P/E/G ratio of 2.30 and a beta of 1.12. Abbott Laboratories has a 12-month low of $68.80 and a 12-month high of $92.45.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $0.95 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.95. The business had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 10.50%. The business’s revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.81 earnings per share. Sell-side analysts forecast that Abbott Laboratories will post 3.24 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $0.36 per share. The ex-dividend date is Tuesday, January 14th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.32. This represents a $1.44 annualized dividend and a dividend yield of 1.57%. Abbott Laboratories’s payout ratio is currently 50.00%.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Further Reading: Trading Ex-Dividend
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.